You just read:

First and Only PARP Inhibitor, Lynparza® (Olaparib) Approved as a First-line Maintenance Therapy Treatment in BRCA-Mutated Advanced Ovarian Cancer

News provided by

AstraZeneca Canada Inc.

May 08, 2019, 07:59 ET